Life Sciences Times, Author at Life Sciences Times

Philips to Invest Over $150 Million in U.S. Manufacturing and R&D Expansion

August 15, 2025

PureTech Launches Celea Therapeutics to Advance Treatment of Serious Respiratory Diseases

August 12, 2025

First Patient Dosed in Phase 3 Trial of Potential Dravet Syndrome Treatment

August 11, 2025

THIS WEEK'S STORIES

Akamis Bio Appoints C4 Therapeutics CEO Andrew Hirsch to Board of Directors

August 12, 2025

Tishman Speyer Provides $25.2 Million Mezzanine Financing for Life Sciences Lab Building

August 15, 2025

Study Points to New Mechanism for Schizophrenia Drug Candidate Evenamide

August 11, 2025

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

Life Sciences Times

TOP AUTHORS

Most Read

Tishman Speyer Provides $25.2 Million Mezzanine Financing for Life Sciences Lab Building

Bayer Brings Popular Mexican Pain Reliever Aspirina to U.S. Market

Philips to Invest Over $150 Million in U.S. Manufacturing and R&D Expansion

Vyome Marks Nasdaq Debut as ‘HIND’ on Indian Independence Day

EDITOR PICKS

Philips to Invest Over $150 Million in U.S. Manufacturing and R&D Expansion

PureTech Launches Celea Therapeutics to Advance Treatment of Serious Respiratory Diseases

First Patient Dosed in Phase 3 Trial of Potential Dravet Syndrome Treatment

THIS WEEK'S STORIES

Akamis Bio Appoints C4 Therapeutics CEO Andrew Hirsch to Board of Directors

Tishman Speyer Provides $25.2 Million Mezzanine Financing for Life Sciences Lab Building

Study Points to New Mechanism for Schizophrenia Drug Candidate Evenamide

POPULAR CATEGORY

ABOUT US

FOLLOW US